Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 16/20 | 1.00 |
| ▸ | EGFR | P00533 | 16/20 | 1.00 |
| ▸ | KDR | P35968 | 2/20 | 0.67 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7127874 | 0.89 | EGFR (0.80) | FLT1EGFRKDRCSNK2A1 | |
| SCHEMBL7128028 | 0.81 | FLT1 (1.00) | FLT1EGFRKDR | |
| SCHEMBL7127729 | 0.80 | FLT1 (1.00) | FLT1EGFRKDR | |
| SCHEMBL7127755 | 0.80 | FLT1 (0.78) | FLT1EGFRKDRCSNK2A1 | |
| SCHEMBL7126210 | 0.78 | EGFR (0.67) | FLT1EGFRKDR | |
| SCHEMBL14506933 | 0.78 | FLT1 (0.75) | FLT1EGFRKDR | |
| SCHEMBL7123632 | 0.78 | FLT1 (1.00) | FLT1EGFRKDR | |
| SCHEMBL7127679 | 0.76 | EGFR (1.00) | FLT1EGFRKDR | |
| SCHEMBL7126916 | 0.76 | FLT1 (0.71) | FLT1EGFRKDR | |
| SCHEMBL5461595 | 0.75 | EGFR (1.00) | FLT1EGFRKDRCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030162795-A1 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | PFIZER INC. | 2003-08-28 | — | — | US | claimed |
| US-20030162795-A1 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | PFIZER INC. | 2003-08-28 | — | — | US | disclosed |
| US-6492383-B1 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | PFIZER INC. | 2002-12-10 | — | — | US | disclosed |
| EP-1028964-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999024440-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162795-A1 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | TYMP, DPYD, HPRT1 | FLT1 1043/4885EGFR 2961/4885KDR 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.